Cosmetic Notification in the Philippines: The ASEAN System and Labeling Rules

Notification, Not Formula Approval

The Philippines follows the harmonised notification scheme under the ASEAN Cosmetic Directive. A company files product information with the FDA, receives a notification acknowledgement, and may then place the product on the market. Regulatory weight sits on post-market surveillance rather than pre-market review.

That is quite different from what many exporters expect, and four consequences follow:

• The FDA does not vouch for your formula. A notification confirms that you declared the product. It is not an endorsement of safety or efficacy, and the responsibility stays with the notifying company.
• You must maintain a Product Information File. Formulation, raw material specifications, manufacturer credentials, safety assessment, stability and compatibility data, and evidence supporting claims all have to exist as a complete dossier available on demand. That dossier is the price of a light front end.
• Notification is product by product. Different products under one brand are filed separately. Shade ranges within a series may be grouped where conditions are met, and those conditions follow current guidance.
• Notifications expire and lapse. Renewal is required, and a material change to the formula, product name, manufacturer or responsible company generally calls for a fresh notification rather than an amendment.

After launch, the FDA conducts market sampling and publishes advisories naming unnotified products or those containing banned substances, and can order withdrawal and recall. Being named costs far more than compliance did: distributors stop selling immediately and e-commerce platforms delist. For how regulated goods are categorised more broadly, see the guide to restricted and regulated imports in the Philippines.

One consequence is commercial rather than regulatory. Because nothing is approved in advance, the burden of showing a product is safe and lawfully placed lands on you at the least convenient moment — when a competitor complains, a marketplace demands documentation, or a consumer reports a reaction. Companies that treat the Product Information File as a live document, updated whenever the formula, supplier or filler changes, answer those requests within hours. Companies that assembled it once to get a filing through usually cannot locate it at all.

Who Can Notify: A Local Entity With an FDA License to Operate

Only a company incorporated in the Philippines and holding an FDA License to Operate can file a notification. A foreign entity cannot file directly, and this is the first real fork in the road.

Three arrangements are common, each with a cost:

1. Build your own entity. Set up a subsidiary or branch, obtain an LTO in the importer or distributor category, and hold every notification yourself. Maximum control, and the regulatory asset stays with the brand — but you carry incorporation, premises, warehousing, staffing and annual compliance costs. On choosing a vehicle, see how to select a company registration agent in the Philippines.
2. Let an exclusive importer or distributor hold the licence. Your local partner files under its own LTO. Fast and cheap to start, but the notification belongs to them. If you change distributors, the products must be notified again from scratch, and your negotiating position weakens noticeably. Write notification ownership and post-termination cooperation into the contract.
3. Appoint a licensed third-party representative. A specialist compliance provider acts as the responsible entity. A reasonable middle path, but verify that its licence category actually covers your product type, and agree an exit mechanism in advance.

The LTO itself comes in categories — manufacturer, trader, distributor covering importation, exportation or wholesaling — and the category must match what you really do. Applying under the wrong category gets the notification bounced at intake. Applications generally require genuine business and storage premises and qualified personnel, and may involve an inspection, so a purely virtual address will not carry an LTO. If you need warehousing before you have your own, how to choose a third-party logistics provider is a useful starting point. Categories, documentary requirements and validity follow current FDA rules.

Whichever route you take, put the exit in writing at the outset: who owns the notifications, what happens to them on termination, and what cooperation the licence holder owes during a transfer. That clause is worth considerably more than the margin points most brands spend three meetings negotiating, because it determines whether a change of partner costs you a fortnight or a selling season.

The Two-Step Sequence: Licence First, Then Each Product

The order is fixed: the LTO comes first, product notification second. Without a valid licence the notification portal simply is not open to you. Brands routinely discover this after the purchase order is placed, sometimes after the goods have shipped.

Step one, the LTO application. Filed through the FDA's electronic portal. Typical requirements include corporate registration documents, the local government business permit, a description and layout of premises and storage conditions, credentials of the designated qualified person, and the required undertakings from the company and that person. The FDA may inspect. Initial and renewal validity differ, and renewals should be started early — you cannot carry on regulated activity during a lapse.

Step two, product notification. Once licensed, file per product. Expect to prepare:

• product name and product type or intended function;
• the complete ingredient list in INCI nomenclature, with proportion information where required;
• name, address and credentials of the manufacturer and filler, with documents executed abroad usually needing authentication or apostille;
• label and packaging artwork;
• a Product Information File which, even if not uploaded, must already exist and be producible on request.

On acceptance you receive a notification acknowledgement and may sell. Do not present that acknowledgement as an approval certificate in marketing, and do not imply FDA endorsement — that framing can itself constitute a prohibited claim.

One scheduling recommendation: treat the LTO and the first batch of notifications as the critical path for market entry, running in parallel with distributor discussions rather than after them. If you are also qualifying suppliers or contract manufacturers, how to choose a sourcing agent in the Philippines covers the due diligence. Yixing can map the whole route through our product access practice.

Budget for iteration as well. First submissions are frequently returned for clarification — an ingredient statement that needs restating, artwork that does not match the declared product name, a manufacturer certificate lacking the right authentication. Build a review cycle into the plan rather than treating the date of first filing as the launch date, and keep the factory informed that artwork and specifications are frozen until the filing clears.

The Two Lines Products Cross: Ingredients and Claims

A completed notification does not make a product compliant. What actually gets products pulled is an ingredient on a prohibited or restricted list, or a claim that crosses into drug territory.

On ingredients. The ASEAN framework carries several annexed lists: substances prohibited outright, substances restricted by concentration, site of application or mandatory warning, and positive lists of permitted colorants, preservatives and UV filters. Three working points matter. The lists are updated, so a formula that cleared review years ago may not clear it now. A positive list means anything not listed is not allowed, which is the opposite of assuming that anything not banned is fine. And several actives that are routine in other markets — certain whitening, anti-acne and anti-ageing ingredients — may be restricted here or fall under drug regulation entirely.

On claims. The legal definition of a cosmetic is limited to cleansing, perfuming, changing appearance, correcting body odour, protecting or keeping in good condition. The moment a product claims to treat, prevent or diagnose disease, or to alter the structure or function of the body, it stops being a cosmetic and becomes a drug, subject to an entirely different and much heavier approval regime. Common crossings include claiming to treat acne or eczema, claiming antibacterial action at a medical level, claiming to change skin physiology, or implying a product substitutes for medical treatment.

Translated marketing copy is the highest-risk area of all: wording that is compliant in the origin market often crosses the line once rendered locally. Note too that the exposure is not limited to the label. Live-selling scripts, social posts and marketplace product pages carry the same risk, and enforcement lands on the local licence holder. Extend claim review to every outward-facing asset, and put claim boundaries and liability into distributor and influencer contracts. List versions and interpretation follow current FDA and ASEAN documents.

What the Label Must Carry

Labels are the first thing an inspector reads and the easiest way to lose an entire shipment, because a single missing particular can trigger withdrawal. Under the harmonised requirements, a cosmetic label generally must show:

• Product name and function, with the function stated separately if it is not obvious from the name.
• Directions for use, including any conditions or limits on use.
• The full ingredient list in INCI nomenclature in descending order of content, with low-content ingredients ordered under the applicable rule and colorants declared in the prescribed manner.
• Country of manufacture.
• Net content, expressed in the prescribed units.
• Batch number, traceable to a specific production batch.
• Date of minimum durability or expiry, presented in the prescribed format.
• Name and address of the responsible company — the licensed entity placing the product on the Philippine market, not only the foreign brand owner.
• Special precautions and warnings, reproduced verbatim where a restricted ingredient requires them.

Three errors recur. Reusing artwork prepared for another export market, which almost always omits the local responsible company. Covering original information with a sticker, so that a mandatory particular is obscured or the sticker peels. And listing ingredients under trade names instead of INCI names. Language requirements follow current FDA rules.

Do the full label comparison before mass production and leave time for a revision cycle. The cost of a label reprint is not the printing — it is a container sitting in a warehouse through the selling season. Where goods are examined at the border, any mismatch between label and notification data invites a hold; see how to choose a customs broker for the clearance side.

One habit is worth adopting from the first shipment: keep the approved artwork, the notification record and a retained physical sample of each batch together as a set. When an inspector or a marketplace asks what was actually on shelf in a given period, being able to produce the matching three within a day changes the tone of the entire conversation — and where a recall is ordered, that same set is what defines its scope.

Customs Clearance and Five Recurring Mistakes

A notification does not, by itself, get goods through the port. Clearance requires the licensed entity, the valid notification and the import declaration to line up. Any mismatch is grounds for a hold.

The standard chain runs: the licensed local entity acts as importer and holds the notifications, trade documents are assembled (commercial invoice, packing list, bill of lading), the broker lodges the declaration and, where required, secures the relevant FDA clearance for the shipment, and the goods are released after examination. Some categories carry additional pre-arrival steps, and requirements follow current FDA and Bureau of Customs rules.

Five mistakes come up again and again:

1. Shipping before notifying. The cargo arrives, the notification is incomplete, and demurrage accrues daily. The usual endings are re-export or abandonment.
2. Notification holder is not the importer. The supply contract names company A while the notification sits with company B, and the declaration does not reconcile.
3. Product does not match the notification. The factory reformulated, changed fillers, or renamed the product, and nobody updated the filing.
4. Treating samples as exempt. Trade show and testing samples are still regulated goods; bringing them in as personal effects is a poor bet.
5. Changing distributors without a handover. The notifications belong to the outgoing partner, the incoming one has to start over, and the brand goes out of stock in between.

One point that argues against speed: if your range includes borderline categories — actives with strong functional claims, or care products containing pharmaceutical-grade ingredients — get the classification settled before you sign distribution deals. A drug classification means a different pathway on a different timescale, and pushing it with a cosmetic budget and schedule usually fails. Yixing can assess classification and the full route through our product access and compliance team. Yixing is an SEC-registered company (CS202009551) holding Bureau of Immigration accreditation CA-202624381-1 (valid to 30 June 2027) and DOLE and PRA accreditations. We are a private consultancy with no affiliation to any government agency and make no promises about regulatory outcomes.